Cite
HARVARD Citation
Gandara, D. et al. (2021). Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. Journal for immunotherapy of cancer. 9 (3), p. . [Online].